Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

ConferenceFoundayoretatrutideeloraTZPPositive

AI Analysis

Summary

Eli Lilly announced it will present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026. Pivotal TRIUMPH-2 results demonstrated retatrutide delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes, while ACHIEVE-4 reaffirmed Foundayo's benefits in type 2 diabetes.

Clinical Trial Data

Primary Endpoint

Met

Importance:6/10

Sentiment:

0.70

cardiometabolic healthweight lossA1C improvementstriple hormone receptor agonistEASD 2026TRIUMPH-2ACHIEVE-4

Related Companies

$LLY

Read the original article

Published by PR Newswire Pharma on September 15, 2026 10:45 AM

Read Original